Killing breast cancer cells in a way that trains the immune system to recognize and destroy residual cancer cells could offer ...

Scientists from EMBL Heidelberg and the University of Virginia have uncovered an intriguing mechanism by which cells adapt to ...

Researchers found that DNA mutations from antiviral enzymes and chemotherapy fuel early bladder cancer, while abnormal ...

根据威尔康奈尔医学、纽约长老会医院、纪念斯隆凯特琳癌症中心和其他机构进行的一项多中心研究，与其他变异相比，KRAS基因的常见突变与胰腺导管腺癌 (PDAC)的总生存率提高有关，部分原因是该突变似乎导致侵袭性较小，生物活性较弱。 根据威尔康奈尔医学、纽约长老会医院、纪念斯隆凯特琳癌症中心和其他机构进行的一项多中心研究，与其他变异相比，KRAS基因的常见突变与胰腺导管腺癌 ...

Chloride ion flows that enter the cells play an important role in the duplication of glioblastoma cells, a highly aggressive ...

A combination of two types of therapeutic agents selectively killed breast cancer cells in a clinical trial, offering hope ...

The researchers used the CellSearch assay to measure circulating tumor cells and determine the response to certain treatments as well as survival outcomes.

T cell therapy has achieved notable success in treating blood cancers. However, it has been largely ineffective against solid ...

These breakthrough therapies have not only improved survival rates but also provided more targeted, less invasive options.

Analyzing the genetics of patients that responded well to checkpoint blockade revealed mutations in the gene Asxl1 in immune T cells. Disrupting the Asxl1 gene in T cells enhanced response to immune ...

Triple negative breast cancer (TNBC) remains the most aggressive and deadly type of breast cancer, but new findings from cancer researchers are pointing the way toward therapeutic strategies that ...

Renal cell carcinoma (RCC) is the third most common cancer of the urinary system. There is a pressing need for specific biomarkers for advanced/metastatic RCC to enhance diagnostic accuracy and ...